Mycophenolate mofetil and reduced doses of cyclosporine in pediatric liver transplantation with chronic renal dysfunction: Changes in the immune responses

Pediatric Transplantation

Volumn 8, Issue 5, 2004, Pages 454-459

  Ferraris, Jorge R ^a,c   Duca, Pablo ^a   Prigoshin, Norma ^a   Tambutti, Monica L ^a   Boldrini, Gustave ^a   Cardoni, Rita L ^b   D'Agostino, Daniel ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c NONE   (Argentina)

Author keywords

Chronic renal dysfunction; Cyclosporine; Cytokine; Liver transplantation; Mycophenolate mofetil

Indexed keywords

CYCLOSPORIN; GAMMA INTERFERON; INTERLEUKIN 10; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE TOXICITY; ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CELL PROLIFERATION; CHRONIC GRAFT REJECTION; CHRONIC TOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOKINE RELEASE; CYTOLYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; KIDNEY BIOPSY; KIDNEY FUNCTION; LIVER DISEASE; LIVER FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NEPHROTOXICITY; RISK BENEFIT ANALYSIS; SIDE EFFECT;

ADOLESCENT; CHILD; CYCLOSPORINE; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERFERON-ALPHA; INTERLEUKIN-10; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 4644247615     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2004.00172.x     Document Type: Article

References (30)

1. IWATSUKI S, STARZL TE, TODO S. et al. Experience in 1000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc 1988: 20 (Suppl 1): 498-504.
2. FISHER NC, NIGHTINGALE PG, GUNSON BK, LIPKIN GW, NEUBERGER JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998: 66: 59-66.
3. BUNN SK, ARORA N, MILFORD D. et al. Renal dysfunction after pediatric liver transplantation. J Pediatr Gastroenterol Nutr 2000: (Suppl 2): 549.
4. D'ACOSTINO D, DUCA P, GALLO G, FERRARIS J. Chronic renal failure following long term outcome of pediatric liver transplantation. J Pediatr Gastroenterol Nutr 2000: (Suppl. 2): 550.
5. MORRIS RE. Immunopharmacology of new xenobiotic immunosuppressive molecules. Semin Nephrol 1992: 12: 304-314.
6. ALLISON AC, EUGUI EM. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 1994: 26: 3205-3210.
7. ALLISON AC, ALMQUIST SJ, MULLER CD, EUGUI EM. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc 1991: 23 (Suppl. 2): 10-14.
8. SOLLINGER HW, for the US Renal Transplantation Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995: 60: 225-232.
9. MCDIARMID SV. Mycophenolate mofetil in liver transplantation. Clin Transpl 1996: 10: 140-145.
10. FISHER RA, HAM JM, MARCOS A. et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver-transplantation. Transplantation 1998: 66: 1616-1621.
11. SCHLITT HJ, BARKMANN A, BÖKER KH. et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomized controlled study. Lancet 2001: 357: 587-591.
12. CHARDOT C, NICOLUZZI JE, JANSSEN M. et al. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation 2001: 71: 224-229.
13. NOBILI U. Mycophenolate mofetil in pediatric liver transplant patients with renal dysfunction: preliminary data. Pediatr Transplant 2003: 7: 454-457.
14. FERRARIS JR, TAMBUTTI ML, REDAL MA, BUSTOS D, RAMIREZ J, PRIGOSHIN N. Conversion from azathioprina to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection. Transplantation 2000: 70: 297-301.
15. BACH JF, FEUTREN G, NOEL LH. et al. Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels. Transplant Proc 1990: 22: 1296-1298.
16. FALKENHAIN ME, Cosio FG, SEDMARK DD. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996: 62: 364-370.
17. ROMERO F, RODRIGUEZ-ITURBE B, PARRA G, GONZALEZ L, HERRERA-ACOSTA J, TAPIA E. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999: 55: 945-955.
18. PAPATHEODORIDIS GV, O'BEIRNE J, MISTRY P, DAVIDSON B, ROLLES K, BURROUGHS AX. Mycophenolate mofetil: an alternative maintenance immunosuppressant in liver transplantation, which improves renal function. Hepatology 1998: 28 (Suppl.): 267A.
19. MOORE KW, O'GARRA A, DE WAAL MALEFYT R, VIEIRA P, MOSMANN TR. Interleukin-10. Annu Rev Immunol 1993: 11: 165-190.
20. EGI H, HAYAMIZU K, OHMORI I, KITAYAMA T, ASAHARA T. Upregulation of intragraft interleukin-10 by infusion of granulocyte colony-stimulating factor-mobilized donor leukocytes. Transpl Int 2002: 15: 479-485.
21. SHIN GT, KHANNA A, DING R. et al. In vivo expression of transforming growth factor-beta 1 in humans: stimulation by cyclosporine. Transplantation 1998: 65: 313-318.
22. PASCUAL M, SUINFORD RD, INGELFINGER JR, WILLIAMS WW, COSIMI AB, TOLKOFF-RUBIN N. Chronic rejection and chronic cyclosporin toxicity in renal allograft. Immunol Today 1998: 19: 514-519.
23. DI PAOLO S, SCHENA A, STALLONE G. et al. Captopril enhances transforming growth factor (TGF)-beta 1 expression in peripheral blood mononuclear cells: a mechanism independent from angiotensin converting enzyme inhibition? A study in cyclosporine-treated kidney-transplanted patients. Transplantation 2002: 74: 1710-1715.
24. HOFFMANN MW, WONIGEIT K, STEINHOFF G, HERZBECK H, FLAD HD, PICHLMAYR R. Production of cytokines (TNF-alpha, IL-1 beta) and endotelial cell activation in human liver allograft rejection. Transplantation 1993: 55: 329-335.
25. WARLE MC, FARHAN A, METSELAAR HJ. et al. In vitro cytokine production of TNF-α and IL-13 correlates with acute liver transplant rejection. Human Immunol 2001: 62: 1258-1265.
26. MOR E, ORTEGEL JW, MENO J. et al. Genetic cytokine polymorphism in liver allograft recipients. Transplantation 2001, 69: S119.
27. THYBERG J, HEDIN U, SJOLUND M, PALMBERG L, BOTTGER BA. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis 1990: 10: 966-990.
28. ALLISON AC. Mechanisms of action of mycophenolate mofetil in preventing chronic rejection. Transplant Proc 2002: 34: 2863-2866.
29. WEIMER R, MYTILINEOS J, FEUSTEL A. et al. Mycophenolate mofetil-based immunosuppression and cytokine genotypes: effects on monokine secretion and antigen presentation in long-term renal transplant recipients. Transplantation 2003: 75: 2090-2099.
30. CHANDRAKER A, AZUMA H, NADEAU K. et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998: 101: 2309-2318.